Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the future of HER2+ breast cancer treatment.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More